Unveiling Merck (MRK) Q4 Outlook: Wall Street Estimates for Key Metrics

Wall Street analysts forecast that Merck (MRK) will report quarterly earnings of $1.69 per share in its upcoming release, pointing to a year-over-year increase of 5533.3%. It is anticipated that revenues will amount to $15.56 billion, exhibiting an increase of 6.4% compared to the year-ago quarter.Over the last 30 days, there has been a downward revision of 2.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.With that in mind, let's delve into the average projections of some Merck metrics that are commonly tracked and projected by analysts on Wall Street.The combined assessment of analysts suggests that 'Sales- Oncology- Keytruda' will likely reach $7.73 billion. The estimate suggests a change of +17% year over year.The consensus estimate for 'Sales- Animal health' stands at $1.34 billion. The estimate suggests a change of +5.2% year over year.The consensus among analysts is that 'Sales- Hospital Acute Care- Zerbaxa' will reach $65.05 million. The estimate suggests a change of +6.6% year over year.According to the collective judgment of analysts, 'Sales- Hospital Acute Care- Prevymis' should come in at $206.08 million. The estimate indicates a change of +17.8% from the prior-year quarter.Based on the collective assessment of analysts, 'Sales- Oncology- Keytruda - U.S.' should arrive at $4.65 billion. The estimate indicates a change of +17% from the prior-year quarter.The average prediction of analysts places 'Sales- Oncology- Keytruda - International' at $3.09 billion. The estimate points to a change of +17.1% from the year-ago quarter.It is projected by analysts that the 'Sales- Oncology- Alliance revenue- Lynparza - U.S.' will reach $181.24 million. The estimate indicates a change of +7.9% from the prior-year quarter.Analysts forecast 'Sales- Oncology- Alliance revenue- Lynparza - International' to reach $176.33 million. The estimate suggests a change of +20% year over year.Analysts expect 'Sales- Oncology- Alliance revenue- Lenvima - U.S.' to come in at $173.51 million. The estimate indicates a change of -4.1% from the prior-year quarter.Analysts' assessment points toward 'Sales- Oncology- Alliance revenue- Lenvima - International' reaching $80.77 million. The estimate points to a change of +79.5% from the year-ago quarter.Analysts predict that the 'Sales- Hospital Acute Care- Zerbaxa - U.S.' will reach $35.78 million. The estimate suggests a change of +8.4% year over year.The collective assessment of analysts points to an estimated 'Sales- Hospital Acute Care- Zerbaxa - International' of $29.27 million. The estimate indicates a year-over-year change of +4.5%.View all Key Company Metrics for Merck here>>>Merck shares have witnessed a change of -0.2% in the past month, in contrast to the Zacks S&P 500 composite's +2.9% move. With a Zacks Rank #3 (Hold), MRK is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks